Geneva, Switzerland, May 4th 2015 – EspeRare today announced that the European Medicines Agency (EMA) has granted an Orphan Drug Designation (ODD) for rimeporide, its lead compound for the treatment of Duchenne muscular dystrophy (DMD). DMD is a rare, life-threatening disease affecting boys early in childhood that causes muscle weakness and muscle loss. It is the most common and serious form of paediatric muscular dystrophies.
Find an actor

BioAlps Networking Day 201829.11.2018

L'événement aura lieu au SICHH le 29 novembre 2018 au blueFACTORY à Fribourg

AMAL Therapeutics raises 33.2 million dollars

The Geneva-based startup just announced the completion of its Series B financing round, raising in total CHF 33.2...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn